Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.intimp.2020.106869 http://scihub22266oqcxt.onion/10.1016/j.intimp.2020.106869 32889241!7402206!32889241     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+Immunopharmacol 2020 ; 88 (ä): 106869 Nephropedia Template TP {{tp|p=32889241|t=2020. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial |pdf=|usr=}}{{32889241}} gab.com Text Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial JO: Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32889241 #FOAvip BACKGROUND: The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms to severe complications, including acute respiratory distress syndrome. In this syndrome, inflammatory cytokines are released after activation of the inflammatory cascade, with the predominant role of interleukin (IL)-6. The aim of this study was to evaluate the effects of tocilizumab, as an IL-6 antagonist, in patients with severe or critical SARS-CoV-2 infection. METHODS: In this prospective clinical trial, 76 patients with severe or critical SARS-CoV-2 infection were evaluated for eligibility, and ultimately, 42 patients were included. Tocilizumab was administered at a dose of 400?mg as a single dose via intravenous infusion. Primary outcomes included changes in oxygenation support, need for invasive mechanical ventilation, and death. Secondary outcomes included radiological changes in the lungs, IL-6 plasma levels, C-reactive protein levels, and adverse drug reactions. The data were analyzed using SPSS software. RESULTS: Of the 42 included patients, 20 (48%) patients presented the severe infection stage and 22 (52%) were in the critical stage. The median age of patients was 56?years, and the median IL-6 level was 28.55?pg/mL. After tocilizumab administration, only 6 patients (14%) required invasive ventilation. Additionally, 35 patients (83.33%) showed clinical improvement. By day 28, a total of 7 patients died (6 patients in the critical stage and 1 patient in the severe stage). Neurological adverse effects were observed in 3 patients. CONCLUSIONS: Based on the current results, tocilizumab may be a promising agent for patients with severe or critical SARS-CoV-2 infection, if promptly initiated during the severe stage. Twit Text FOAVip Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial ????Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32889241 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32889241 #FOAvip English Wikipedia <ref>{{Cite pmid|32889241}}</ref> Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial #MMPMID32889241 Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P Int Immunopharmacol 2020[Nov]; 88 (ä): 106869 PMID32889241show ga BACKGROUND: The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms to severe complications, including acute respiratory distress syndrome. In this syndrome, inflammatory cytokines are released after activation of the inflammatory cascade, with the predominant role of interleukin (IL)-6. The aim of this study was to evaluate the effects of tocilizumab, as an IL-6 antagonist, in patients with severe or critical SARS-CoV-2 infection. METHODS: In this prospective clinical trial, 76 patients with severe or critical SARS-CoV-2 infection were evaluated for eligibility, and ultimately, 42 patients were included. Tocilizumab was administered at a dose of 400?mg as a single dose via intravenous infusion. Primary outcomes included changes in oxygenation support, need for invasive mechanical ventilation, and death. Secondary outcomes included radiological changes in the lungs, IL-6 plasma levels, C-reactive protein levels, and adverse drug reactions. The data were analyzed using SPSS software. RESULTS: Of the 42 included patients, 20 (48%) patients presented the severe infection stage and 22 (52%) were in the critical stage. The median age of patients was 56?years, and the median IL-6 level was 28.55?pg/mL. After tocilizumab administration, only 6 patients (14%) required invasive ventilation. Additionally, 35 patients (83.33%) showed clinical improvement. By day 28, a total of 7 patients died (6 patients in the critical stage and 1 patient in the severe stage). Neurological adverse effects were observed in 3 patients. CONCLUSIONS: Based on the current results, tocilizumab may be a promising agent for patients with severe or critical SARS-CoV-2 infection, if promptly initiated during the severe stage. |Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/*therapeutic use[MESH] |Antiviral Agents/administration & dosage/adverse effects/*therapeutic use[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/mortality/virology[MESH] |Female[MESH] |Humans[MESH] |Infusions, Intravenous[MESH] |Interleukin-6/*blood[MESH] |Kaplan-Meier Estimate[MESH] |Lung/diagnostic imaging/virology[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/mortality/virology[MESH] |Prospective Studies[MESH] |Respiration, Artificial[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]Promising effects of tocilizumab in COVID-19: A non-controlled, prospe(epmc).pdf DeepDyve Pubget Overpricing